Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease

Alba Di Pardo1†, Silvia Alberti1†, Vittorio Maglione1, Enrico Amico1, Etty P Cortes2, Francesca Elifani1, Giuseppe Battaglia1, Carla L Busceti1, Ferdinando Nicoletti1,3, Jean Paul G Vonsattel2 and Ferdinando Squitieri1*

Abstract

Background: Huntington Disease (HD) is a neurodegenerative disorder resulting from the expansion of polyglutamine stretch in the huntingtin protein (Htt). Mutant HTT (mHtt) leads to progressive impairment of several molecular pathways that have been linked to disease pathogenesis. Defects in the production of a number of neurotrophic factors have been described as important determinants contributing to the development of HD. We have previously demonstrated that production of transforming growth factor-β1 (TGF-β1) is also deregulated in HD. Peripheral levels of TGF-β1 were markedly reduced early in the disease and returned to normal levels with disease severity. However, the cause and the biochemical origin of such abnormalities are still unclear.

Results: We report here that the abnormal production of peripheral TGF-β1 depends on the changes in the percentage of TGF-β1-producing macrophages along disease course. Variation in the number of TGF-β1-producing macrophages resulted from differential activation state of the same cells, which displayed phenotypic and functional heterogeneity throughout the clinical course of HD. We further demonstrated that, similar to the periphery, the number of TGF-β1-immunoreactive cells in human post-mortem brain with HD, varied with neuropathological changes.

Conclusions: Our data indicate that reduced bioavailability of TGF-β1 in the serum of HD subjects is attributable to the variation of the number of TGF-β1-producing macrophages. Macrophages display a differential ability to produce TGF-β1, which reflects diversity in cells polarization throughout the disease course. Besides elucidating the biochemical origin of TGF-β1 fluctuations in HD, our study highlights an interesting parallelism between periphery and central compartment and underlines the potential of TGF-β1 as a possible indicator suitable for prediction of disease onset in HD.

Keywords: Cytokines in Huntington disease, TGF-β1, Monocytes-derived macrophages, Macrophages polarization

Background

Huntington disease (HD) is a progressive neurodegenerative disorder, caused by an expanded CAG repeat within HTT gene encoding an abnormal long polyglutamine (polyQ) stretch in the huntingtin protein (Htt). Elongated polyQ tract contributes to either gain-of-toxic function of Htt or loss-of-function of many other proteins, resulting in a broad array of cell dysfunctions within and out the nervous system [1]. In the brain, progressive striatal atrophy, degeneration of cortico-striatal fibers and glial activation are characteristic features of HD and represent early events in the disease course. Although the disease has traditionally been described as a disorder purely of the brain, abnormalities outside the central nervous system (CNS) are commonly found in HD [2]. Mutant huntingtin (mHtt) has been widely described to be highly expressed in immune cells which are becoming increasingly interesting in the study of neurodegenerative disorders as well as in the pathogenesis of the disease [3,4]. Defective regulation of growth factors, including brain-derived neurotrophic factor (BDNF) [5] and glial-derived neurotrophic factor (GDNF) [6] has been reported to affect CNS function [7] and to contribute to
the pathogenesis of the disease [5,8]. Production of transforming growth factor-β1 (TGF-β1), a growth factor with established neuroprotective function and powerful anti-inflammatory properties [9] is also reported altered in HD [10]. Levels of TGF-β1 dynamically vary with HD development in both central and peripheral districts [10]. TGF-β1 plays a critical role in the regulation of several physiological processes including cell cycle control, cell differentiation and immune functions [11]. In addition to that, TGF-β1 contributes to maintain neuronal survival and integrity of CNS and regulates microglia activation [12]. Perturbations of the TGF-β1 signaling are involved in many neurodegenerative disorders [13]. An aberrant expression of TGF-β1 receptor II (TGFRII) has been reported in the brain of Alzheimer’s disease (AD) patients [14-17]. Reduced TGF-β1 signaling increases amyloid deposition and neurodegeneration in transgenic AD mice [13]. The role of TGF-β1 has been also investigated in several other neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) [18], Parkinson disease (PD) and Prion diseases [9]. Reduced levels of TGF-β1 in the brain increase susceptibility to excitotoxic injury and neurodegeneration in heterozygous TGF-β1 knockout mice [12].

Under normal conditions, the expression of TGF-β1 is minimal and drastically up-regulates under pathologic circumstance, during which it plays a key role in the coordination of inflammatory responses and tissues recovery [19-21], TGF-β1 is predominantly synthesized by neurons and glial cells, within the CNS, and by platelets and monocytes/macrophages in the peripheral tissues [22,23].

Macrophages display remarkable plasticity that enables them to perform distinct and even opposing function, such as release of either inflammatory or anti-inflammatory cytokines and growth factors, in response to different environmental cues [24]. Depending on the activation state, macrophages can be designed as either classical activated (M1), with pro-inflammatory properties, or alternatively activated (M2) cells, which mediate anti-inflammatory response [25]. Under physiological condition, macrophages, like glia, interact with their surroundings and provide protective cytokines and neurotrophins. Upon insult, both cell populations can become pathologically activated leading to neuro-inflammation, and/or neurodegeneration by altering expression of many neurotrophic factors [26].

In this study, we demonstrated that changes of peripheral TGF-β1 levels in HD depend on the variation in the percentage of TGF-β1-producing monocytes-derived macrophages along disease course. The differential capacity of macrophages to produce TGF-β1 reflects different cell phenotypes during the disease. After an early pro-inflammatory phenotype, macrophages switched towards an anti-inflammatory profile with disease progression. Although not completely elucidated, changes of nuclear factor-κB (NF-κB)-p65 expression/regulation may likely represent one of the molecular mechanisms governing macrophages heterogeneity in HD.

Results
Abnormal levels of peripheral TGF-β1 in HD depend on monocytic/macrophagic cell subset
In order to identify what peripheral cell population primarily determined fluctuation of TGF-β1 levels in the serum of HD patients we examined the contribution of each whole blood cell subset at producing the cytokine by flow cytometry analysis (FACS). We first demonstrated similar absolute counts (n° cells ×10³/ml) of whole blood cell subsets (lymphocytes, monocytes and granulocytes) in HD individuals (Table 1) and controls (Additional file 1). Each cell subset was then examined to determine the relative contribution to TGF-β1 production. The percentage of lymphocytes and granulocytes producing TGF-β1 was similar in HD individuals and healthy controls (Figure 1A, B). Conversely, the percentage of TGF-β1-producing (TGF-β1⁺) monocytes was markedly low in pre-manifested (pre-HD) and clinical stage I subjects and gradually increased in advanced-stage HD (HD) patients up to control values (Figure 1C, Additional file 2). Analysis of TGF-β1 intracellular content, reported as mean fluorescence unit (MFU), in TGF-β1⁺ cells, did not differ significantly among all the groups (Figure 1D), suggesting no perturbation in the synthesis of the neurotrophin. On the other hand, immunoblotting analysis on total monocyte population showed that TGF-β1 protein expression varied coherently with the changes of the percentage of TGF-β1-producing monocytes along disease stages (Additional file 3).

Similar to monocytes, monocytes-derived macrophages from pre-HD subjects and clinical stage I patients showed only a small portion of TGF-β1⁺ cells when compared to cells derived from advanced HD stage patients and controls (Figure 2A, Additional file 4). No difference in the number of TGF-β1⁺ cells was detected between severe symptomatic patients and normal control subjects (Figure 2A), or between controls themselves (Additional file 5). MFU values relating to macrophages were significantly higher in pre-HD subjects as compared to controls (Figure 2B), indicative of an increased expression of intracellular TGF-β1 per cell at the early stage of the disease. Consistently, analysis of gene expression showed a robust increase of TGF-β1 mRNA levels in pre-HD compared either with control subjects or more advanced HD patients (Figure 2C). No difference in both MFU and TGF-β1 gene expression was detected between later stage HD patients and controls (Figure 2B,C).

Macrophages display different degrees of polarization throughout HD course
In an attempt to investigate whether dynamic change of TGF-β1-production during HD course was due to
Table 1 Demographic and clinical data of HD patients

|      | Number (M,F) | Age (24-77 yrs) | TFC (13–0) | CAG repeats [27-43] | AO [16-69] | HD DI (yrs) [40,41] | DB (108–759) | DS (100–0) | UHDRS1 (1–100) | UHDRS2 (248–7) | UHDRS3 (0–88) | UHDRS4 (0–25) | MMSE (0–30) |
|------|--------------|-----------------|------------|---------------------|------------|---------------------|-------------|------------|----------------|----------------|--------------|---------------|-------------|
| Pre-HD | 14           | 35,4 ± 4,4      | 13         | 44,0 ± 2,4          | -          | −13.8 ± 7.9        | 99,7 ± 0,9  | 58 ± 4,3   | 278,3 ± 33,1    | 6,2 ± 6,9       | 25,0 ± 0,0   | 27,8 ± 1,3    |
| I HD   | 15 (M = 9, F = 6) | 46,9 ± 8,4      | 11,8 ± 1,1 | 44,1 ± 2,2          | 44,2 ± 8,1 | −1,6 ± 6,2         | 389,5 ± 70,2| 92,1 ± 4,1 | 24,1 ± 7,9       | 1866 ± 54,1     | 16,5 ± 7,5   | 23,7 ± 1,7   | 26,9 ± 1,7  |
| II HD  | 36 (M = 17, F = 19) | 55,4 ± 10,9     | 7,7 ± 0,8  | 43,2 ± 3,0          | 47,1 ± 10,3| 3,9 ± 10,3         | 403,8 ± 124,1| 77,2 ± 6,3| 39,3 ± 12,2       | 132,2 ± 52,6    | 19,7 ± 7,9   | 17,6 ± 4,2   | 23,3 ± 4,5  |
| III HD | 31 (M = 18, F = 13) | 53,6 ± 11,7     | 4,6 ± 1,3  | 44,5 ± 3,5          | 44,1 ± 10,1| 6,7 ± 6,7          | 448,8 ± 110,1| 61,3 ± 11,6| 55,4 ± 12,8       | 89,1 ± 48,8     | 23,4 ± 10,0  | 9,8 ± 5,1    | 20,2 ± 5,0  |
| IV HD  | 10 (M = 4, F = 6) | 59,2 ± 10,5     | 1,6 ± 0,5  | 44,0 ± 3,6          | 46,4 ± 10,2| 11,7 ± 6,1         | 470,7 ± 128,0| 39,0 ± 8,4| 75,8 ± 21,4       | 71,2 ± 44,9     | 23,3 ± 14,2  | 1,3 ± 0,8    | 21,0 ± 5,1  |
| V HD   | 6 (M = 2, F = 4)  | 58,3 ± 13,4     | 0          | 45,0 ± 5,3          | 41,0 ± 15,6| 10,3 ± 5,9         | 499,5 ± 127,0| 22,9 ± 6,4| 90,2 ± 13,4       | 0 ± 0,6         | 0,2 ± 0,4    | 11,4 ± 3,0   |

Control subjects are 46 (M = 19, F = 27; mean age: 49,3 ±10,7). Values are given as mean ± s.d. yrs: years; TFC: total functional capacity; AO: age at onset; HD DI: Huntington Disease Development Index; DB: Disease Burden; DS: Diasability. Score; UHDRS: Unified Huntington Disease Rating Scale; MMSE: Mini Mental State Examination.
a phenotypic heterogeneity of macrophagic cells, we explored cell surface markers associated with either M1 or M2 phenotypes in monocyte-derived macrophages from HD individuals and healthy controls. Pre-HD subjects and clinical I stage HD patients showed a preferential pro-inflammatory M1 phenotype - high percentage of CCR2$^+$CX3CR1$^{-}$ cells- and low percentage of CCR2$^{-}$CX3CR1$^+$ cells (Figure 3A). Macrophages from HD patients in the late stage of the disease, displayed changes in the expression of surface markers in favour of anti-inflammatory M2 phenotype - high frequency of CCR2$^{-}$CX3CR1$^+$ cells – and low percentage of CCR2$^+$CX3CR1$^{-}$ cells (Figure 3B). Expression of M1 and M2 surface markers was further confirmed by RT-PCR (data not shown).

Macrophages phenotype can be identified based also on the production of specific cytokines [27]. Consistent with phenotypic heterogeneity of macrophages in HD, we found that the percentage of pro-inflammatory IL-12$^+$ cells (M1) was significantly increased early in the disease and returned to control values in the late stages HD patients (Figure 3C). Reduction in the frequency of IL-12$^+$ cells in symptomatic HD patients, was associated with a concomitant increase in the percentage of anti-inflammatory IL-10$^+$-producing (IL-10$^+$) macrophages (M2 phenotype) (Figure 3D). Despite such phenotypic diversity, however, the intracellular content of both IL-12 and IL-10 did not differ significantly among all the groups (data not shown).

NF-κB pathway contributes to macrophages heterogeneity in HD

In order to clarify the possible molecular mechanism underlying the differential pattern of macrophages activation along disease course, we investigated the potential involvement of NF-κB in the promotion of distinct macrophage phenotypes. Analysis of protein expression indicated that monocytes-derived macrophages from pre-HD subjects displayed higher levels of NF-κB-p65 compared to symptomatic HD patients (Figure 4A). No differences were observed between healthy controls and symptomatic HD patients (Figure 4A). Interestingly, immunohistochemical staining for NF-κB-p65 in different graded post-mortem brain tissues showed NF-κB-p65 expression changing profile similar to that observed in periphery (Figure 4B).

TGF-β1 levels in human HD post-mortem striatum change with disease-stages

Immunohistochemical analysis in post-mortem human brain striatum, obtained from HD subjects and healthy controls, showed variation of the number of TGF-β1 immunoreactive cells during disease progression (Figure 5, Table 2) with a changing profile similar to that observed in periphery. TGF-β1 immunoreactivity was first detected in pathological grade II HD brain tissues and gradually increased with disease severity reaching a peak in grade III-IV HD brains (Figure 5A, B).
TGF-β1 is mainly expressed by astrocytes in HD brains

In order to identify what cell population was primarily implicated in the synthesis of TGF-β1 in brain tissues along HD course, immunohistochemical studies were conducted by using marker of specific cell types. First, we investigated the involvement of microglia by using the microglia-specific Ionized calcium-binding adaptor molecule 1 (Iba1). Our data showed no co-localization between Iba1 and TGF-β1 immunopositive cells in none of the neuropathological grades of HD brains (Additional file 6), suggesting therefore, a poor implication of this cell type. Conversely, analysis of Glial Fibrillary Acid Protein (GFAP) immunoreactivity revealed a preferential implication of astrocytes in the synthesis of TGF-β1 in HD brains (Figure 6). GFAP immunoreactive cells showed co-localization with TGF-β1 positive cells starting from grade II HD patients up to later grades (Figure 6).

Percentage of TGF-β1+ macrophages correlates with clinical and genetic parameters

When we explored possible relationships between TGF-β1 and clinical parameters, we observed a statistically
significant positive correlation between the percentage of TGF-β+ cells and age at onset (Figure 7A), disease burden (Figure 7B), HD development index (Figure 7C), as well as motor performance score (UHDRS1) (Figure 7D). A significant negative correlation was also found with disability scale (Figure 7E), functional test scores (UHDRS4) (Figure 7F) and cognitive test scores (UHDRS2 and MMSE) (Figure 7G, H). Instead, we did not find any correlation between TGF-β1+ cells and the behavioural test score (UHDRS3) (Figure 7I).

Discussion
Changes in the levels and the activities of endogenous neurotrophic factors are considered critical for the progression of degeneration in CNS diseases [28-30], including HD [31]. Defective bioavailability of such factors may have profound impact on the homeostasis of the brain, affecting neuroplasticity and leading to neuronal death [5]. Recently, we have reported dynamic variations of TGF- β1 levels throughout the natural course of the disease and argued that the defective bioavailability of
the cytokine early in the disease might contribute to the development of HD [10].

In the present study, we show that changes of peripheral TGF-β1 levels may be attributable to an aberrant production by peripheral monocytic/macrophagic. The number of TGF-β1-producing cells varied with disease progression and displayed a profile that was similar to the pattern of TGF-β1 levels in the serum of HD patients [10]. Therefore, lower number of TGF-β1+ monocytes/macrophages in pre-HD subjects, might potentially explain the reduced bioavailability of TGF-β1 in the serum of HD individuals at similar clinical stage. Both peripheral monocytic and macrophagic cell subsets from pre-HD subjects showed a significant reduction of TGF-β1+ cells when compared to controls and late stage HD patients. The lower percentage of TGF-β1+ monocytes/macrophages in pre-HD subjects, and was accompanied by remarkable increase of percentage of IL-10+ macrophages. Changes in the percentage of both cytokines-producing cells would explain the disease stage-dependent variation of cytokines levels in HD individuals [2]. While increased percentage of IL-12+ macrophages (M1) may explain the inflammation state in the early stage of the disease, elevated IL-10 producing macrophages (M2) in advanced disease stage may enhance an adaptive immune response, convey neuroprotective signals and, possibly, outline a potential repairing attempt of tissues in HD. Yet, the mechanisms that govern macrophage polarization to different phenotypes remain to be defined, however, our results suggest that it could be mediated by a variable activity of NF-κB.

NF-κB is widely known for its role in the regulation of inflammation and immune response [37]. It is an inducible heteromeric transcription factor classically composed of p50 and p65 subunits. While p65 possesses a transactivation domain and modulates most of the NF-κB's transcriptional activity, p50 does not [38,39]. Activation of NF-κB promotes M1 macrophage polarization and turns inflammation processes on [40], while its inhibition results in switching the inflammation processes off [41-43]. Dysregulation of NF-κB activity has been implicated in the pathogenesis of multiple diseases such as inflammatory diseases and neurodegenerative disorders [44] including HD [45,46].

Here, we found that NF-κB pathway changed along HD course in both central and peripheral district with similar pattern. Unlike a relatively high expression of NF-κB -p65

---

Table 2 Pathological and clinical data of three control subjects and ten HD patients analysed for TGF-β1 expression in the striatum post-mortem sample

| Patients | Age (years) | Gender | Vonsattel et al’s grade |
|----------|-------------|--------|------------------------|
| 1        | Healthy control | 74     | M                      | CTRL |
| 2        | Healthy control | 67     | M                      | CTRL |
| 3        | Healthy control | 79     | F                      | CTRL |
| 4        | Symptomatic   | 69     | M                      | I    |
| 5        | Symptomatic   | 50     | M                      | II   |
| 6        | Symptomatic   | 58     | M                      | II   |
| 7        | Symptomatic   | 69     | M                      | II   |
| 8        | Symptomatic   | 53     | M                      | III  |
| 9        | Symptomatic   | 56     | M                      | III  |
| 10       | Symptomatic   | 53     | M                      | III  |
| 11       | Symptomatic   | 47     | F                      | IV   |
| 12       | Symptomatic   | 55     | -                      | IV   |
| 13       | Symptomatic   | 49     | F                      | IV   |

CTRL = Healthy controls; I = early HD; II = light HD symptoms; III = moderate HD symptoms; IV = strong HD symptoms.
early in the disease, late HD patients showed levels of NF-κB-p65 reduced compared to early HD subjects and similar to healthy controls. Whether the reduction of NF-κB-p65 in HD patients is due to its selective degradation [47] or depends on anti-inflammatory strategy that macrophages can adopt to counteract the overproduction of inflammatory cytokines needs to be further investigated. Predominance of classical NF-κB heterodimer p50/p65 promotes M1 polarization, whereas M2 polarization is selectively mediated by p50/p50 homodimers [38]. NF-κB-p50 plays a crucial role in the control of M1-vs. M2-driven inflammation by selectively promoting the production of the anti-inflammatory cytokine IL-10 [48] that, in turns promotes the formation of p50/p50 homodimer [49] and inhibits NF-κB activity [38].

Based on this evidence, we hypothesized that the lower availability of NF-κB-p65 late in the disease could correlate with a preferential formation of p50/p50 homodimers thereby driving anti-inflammatory IL-10 gene transcription and subsequently favoring M1-M2 switch. Further studies, however, are needed to address this specific issue. Although little is known about the acquisition and maintenance of M2 phenotype, we believe that M1-M2 switch in HD, in all probability, points out differential roles of peripheral immune cells in the disease induction or progression and may provide protection against overwhelming uncontrolled inflammation. However the underlying molecular mechanism remains to be elucidated. Ongoing studies in our laboratory are examining whether and how mHtt can influence

Figure 6 Astrocytes are mainly involved in the synthesis of TGF-β1 in postmortem HD brains. Representative microphotographs of double fluorescent staining for TGF-β1 and GFAP in post-mortem striatal tissues of control subjects and HD patients, showing co-localization between GFAP and TGF-β1 immunoreactive cells at different pathological grades (from II to IV).
Figure 7 (See legend on next page.)
monocytes-derived macrophages polarization along disease course.

Furthermore, similarly to the periphery, the ability of cells to produce TGF-β1 in the brain varied during disease course, indicative of a possible parallelism between peripheral dysfunction and central defects. TGF-β1 immunoreactive cells were merely detectable in the pathological grade I HD brains and increased dramatically with the severity of pathological grades. TGF-β1 immunoreactivity was paralleled by a gradual increase in GFAP immunopositive reactive astrocytes, indicating a predominant role of these cells to synthesize the neurotrophin in HD brains and highlighting a spread reactive gliosis, a coordinated cellular response representing a single subject.

Conclusions

In summary our study suggests that alteration in monocytes/macrophages homeostasis plays a critical role in establishing the defective production of TGF-β1 in HD and highlights an interesting parallelism between peripheral dysfunction and central defect. We believe that the discovery of macrophages plasticity and an unbalanced M1/M2 phenotype in HD point out a novel biological process that could explain the variable inflammatory profile in HD and eventually define the possible molecular mechanism underlying immune response in the disease. Macrophages heterogeneity in HD likely reflects dynamic variation in the micro-environmental changes during the transition from early to advanced HD stages, which would result in progressive modulation of NF-κB activity in macrophages and their subsequent conversion from M1 to M2 phenotype.

To our knowledge, this is the first evidence of a biological phenomenon never described before in HD. Understanding the biological mechanisms whereby each of the macrophages subset is induced to assume these different roles may provide new opportunities to therapeutically manipulate immune response in HD.

In conclusion, we believe that our study may be of clinical relevance as it has the potential of leading to the identification of possible indicator for predicting HD onset that could advance the design of clinical trials to delay onset or slow progression in HD.

Methods

Subjects

A total of 112 HD subjects (14 pre-HD, 15 stage I, 36 II, 47 III-V), and 46 gender- and age-matched healthy controls divided into 3 groups: 25–40, 41–55, and 55–80 year-old were recruited. Subjects with previous clinical features that were insufficient to warrant a diagnosis of HD, had previously requested a pre-symptomatic genetic test by entering a specific program whose protocol was ethically approved [51]. All HD subjects revealed a CAG repeat expansion mutation and all of them as well as controls were required to sign an informed consent before recruitment in the study. All human experiments were performed in accordance with the Declaration of Helsinki [52].

Control subjects with a suspect of cardiovascular, psychiatric or neurodegenerative disorders other than HD, were excluded from this study. Clinical examinations were conducted using the Unified Huntington’s Disease Rating Scale (UHDRS) to measure motor, cognitive, behavioural and general function [53] and the Mini-Mental State Examination (MMSE) was used to screen general cognitive function [53,54]. Pre-HD subjects included either asymptomatic individuals (total motor score of < 5 in the UHDRS and cognitive and behavioural assessment within the normality) or individuals with soft signs (suspicious clinical features that were insufficient to warrant a diagnosis of HD) [55]. The patients’ age at onset (AO) was retrospectively established by interviews to family members regarding the first neurological manifestations [56], thus excluding, in this first study stage, subjects showing severe cognitive and psychiatric abnormalities that represented a permanent change from the normal state [57]. The predicted years to manifest the disease
were calculated on the basis of the survival analysis formula described by Langbehn et al. (2004) [58]. To estimate the progression of the pathological process from pre-HD stage, we calculated the ‘HD development’ index by combining the predicted years to onset for pre-HD subjects and disease duration (years-from-onset) for patients [59,60]. The disease burden (DB) index was measured according to the previously described formula: age x (CAG-35.5) [61]. The Disability Scale (DS) combines patients’ independence and motor performance, thus taking into account the subjects’ independence on neurological motor impairment [62]. The disease stage was calculated according to the Total Functional Capacity (TFC) score [63].

Human macrophages

Isolation and differentiation
Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation (Ficoll–Hypaque) from freshly drawn venous blood (platelet-free). The cell pellet was layered on a Percoll (GE Healthcare) gradient and the interphase containing monocytic cells was obtained following a 800 g centrifugation [64]. After washing monocytes were seeded into 24-well plates culture containing RPMI (Sigma, San Louis, MO, USA) supplemented with 10% heat inactivated foetal bovine serum (FBS), 2 mM L-glutamine and 100 μg/ml streptomycin and 100 units/ml penicillin. Cells were maintained for 7 days at 37°C in a humidified atmosphere containing 5% CO2 and cultured in presence of 100 ng/ml of macrophages colony stimulating factor (M-CSF, GE-Healthcare) to obtain fully differentiated macrophages [65].

Flow cytometry analysis
Adherent macrophagic cells were detached by vigorous pipetting ice-cold phosphate buffered saline (PBS), centrifuged at 200 × g for 5 minutes and washed with PBS. Cell suspension was then fixed with 4% PFA and incubated with FITC-conjugated anti-human CD80 (EuroBioSciences GmbH, Germany) or an equivalent amount of isotypic control IgG1 (EuroBioSciences GmbH, Germany) for 1 h. CD80-positive macrophages were >90% gated cells (data not shown). For the detection of intracellular cytokines, cells were permeabilized with a buffer containing 0.1% (w/v) tritonX-100, 0.05% (w/v) NaN3 in PBS, and incubated with PE-conjugated anti-human TGF-β1 (R&D Systems, Minneapolis, MN USA) or an equivalent amount of isotypic control IgG2a, k (BD Pharmingen, San José, CA USA) for the detection of monocytes. CD14-positive monocytes were >90% gated cells (data not shown). After washing with PBS, cells were permeabilized with 0.3% tritonX-100 and incubated with PE-conjugated anti-human TGF-β1 (R&D Systems, Minneapolis, MN USA) or an equivalent amount of isotypic control IgG1 (R&D Systems, Minneapolis, MN USA). The percentage of ‘TGF-β1’ cells and the intracellular content of the cytokine (MFU), were scored on the basis of isotype control. All the experiments were performed by using a Becton-Dickinson FACS Calibur flow cytometer (BD, San José, CA, USA).

Real-time RT-PCR analysis

TGF-β1 gene expression in macrophages from pre-HD subjects, HD patients and healthy controls, was measured by quantitative PCR analysis performed on a StepOnePlus instrument (Applied Biosystems) by using the following primer sequences: Fwd: 5′-CGAGGCTGAGCCGACTACTA-3′; Rev: 5′-CTCGGAGGCTTGATGTGTGAA-3′. Briefly, total RNA was extracted using RNeasy kit (Qiagen) according to the manufacturer's instructions and reverse transcribed using Superscript II reverse transcriptase (Invitrogen) and oligo-d(T) primer. Resulting cDNAs were amplified using Power SYBR Green PCR Master Mix (Applied Biosystems) following the manufacturers’ instructions. The level of each mRNA was normalized to that of cyclophilin A (CypA). PCR cycling parameters were as follows: 50°C for 2 min, 95°C for 5 min, followed by 40 cycles of 95°C for 20 s, 60°C for 1 min, and 72°C for 40 s.

Cell subsets from whole blood

Whole blood analyses were carried out in 81 HD individuals (5 pre-HD subjects, 11 I HD, 36 II HD and 29 III-V HD stage patients) and 26 gender- and age-matched healthy controls. Venous blood drawings were collected applying minimal venous stasis in order to minimize cell activation. Whole blood (50 ml) for each sample was fixed with PFA 2% over night at 4°C and circulating cell subsets were distinguished from each other on the basis of physical parameters by using forward (FSC-H, cell volume index) and side light-scatter patterns (SSC-H, cell density index). Cells were then labelled with FITC-conjugated anti-human CD14 (BD Pharmingen, San José, CA USA) or equivalent amount of isotypic control IgG2a, k (BD Pharmingen, San José, CA USA) for the detection of monocytes. CD14-positive monocytes were >90% gated cells (data not shown). After washing with PBS, cells were permeabilized with 0.3% tritonX-100 and incubated with PE-conjugated anti-human TGF-β1 (R&D Systems, Minneapolis, MN USA) or an equivalent amount of isotypic control IgG1 (R&D Systems, Minneapolis, MN USA). The percentage of TGF-β1+ cells and the intracellular content of the cytokine (MFU), were scored on the basis of isotype control. All the experiments were performed by using a Becton-Dickinson FACS Calibur flow cytometer (BD, San José, CA, USA).

Flow cytometry analysis of macrophage M1 and M2 subsets
Analyses of macrophage subsets were carried out in 12 HD individuals (5 early HD subjects and 7 II-III HD stage patients) and 5 gender and age-matched healthy controls. After isolation and differentiation, detached monocytes-derived macrophages were incubated with FITC-conjugated anti-human CCR2 and with PE-conjugated
anti-human CX3CR1 or equivalent amount of isotypic control IgG2b and IgG1, respectively. Cells were incubated for 45 minutes at 4°C in the dark, washed with PBS and acquired to the cytometer. Macrophages were gated on the basis of cells size (FSC-H) and cells density (SSC-H). The percentage of M1 macrophages was identified as CCR2 positive-CX3CR1 negative cells (CCR2⁺CX3CR1⁻) while the percentage of M2 macrophages was identified as CCR2 negative-CX3CR1 positive cells (CCR2⁻CX3CR1⁺) on the basis of isotype controls. All antibodies were purchased from R&D Systems (Minneapolis, MN USA). All the experiments were performed by using a Becton-Dickinson FACSCalibur flow cytometer (BD, San José, CA, USA).

Immunoblotting

Monocytes-derived macrophages from pre-HD subjects, symptomatic HD patients and controls were lysed in lysis buffer containing 20 mM Tris, pH 7.4, 1% Nonidet P-40, 1 mM EDTA, 20 mM NaF, 2 mM Na3V04, and 1:1000 protease inhibitor mixture (Sigma-Aldrich), sonicated with 2 x 10 s pulses and then centrifuged for 10 min at 10,000 x g. For analysis of NF-κB-p65 protein levels, total protein lystate was immunoblotted with anti-NF-κB-p65 (C-20) (1:500; Santa Cruz, sc-372). Ponceau Red staining served as a loading control [66]. TGF-β1 expression was determined by using monoclonal anti- TGF-β1 (T0438) (1:1000; Sigma-Aldrich). A goat polyclonal anti-Talin (C-20; Santa Cruz, sc-7534) was used as loading control for normalization. HRP-conjugated polyclonal secondary antibody (GE-Healthcare) was used at 1:5000 dilution. Protein bands were detected by ECL Prime (GE Health-care) and quantitated with Quantity One (Bio-Rad Laboratories) and/or ImageJ software.

TGF-β1 in human post-mortem brain samples

Post-mortem brain tissues from ten patients at different pathological grades of HD [67] and three healthy controls were examined in this study. Samples were obtained by the New York Brain Bank at Columbia University, New York, USA. Clinical and neuropathological data were summarized in Table 2. Formalin fixed, paraffin-embedded striatal tissues were sectioned at 10 mm. Deparaffinized sections were soaked in 3% hydrogen peroxide to block endogenous peroxidase activity. Sections were treated with Pronase at 37°C for 10 min for antigen retrieval and incubated overnight with monoclonal mouse anti-TGF-β1 antibody (1:1000; Chemicon, CA). TGF-β1 expression was detected by incubating the sample for 1 hour with secondary biotinylated anti-mouse antibody (1:200; Vector Laboratories, Burlingame, CA). Visualization of the immunoreaction was performed with 0.05% 3,3′-diaminobenzidine tetrachloride (DAB) (ABC Elite kit; Vector Laboratories). Control staining was performed without the specific primary antibody. Double fluorescence immunohistochemistry was performed by incubating brain sections over-night with polyclonal rabbit anti-TGF-β1 antibody (1:100; Sigma-Aldrich) and monoclonal mouse anti-GFAP (1:300; Sigma-Aldrich) or polyclonal goat anti-Iba1 (1:200; Abicam). Proteins were then visualized after 1 hour of incubation with secondary Cy3 anti-rabbit (1:200; Chemicon), and fluorescein anti-mouse (1:100; Vector Laboratories) or biotin anti-goat (1:200; Vector Laboratories) and fluorescein anti-biotin (1:100; Vector Laboratories) antibodies.

Statistical analysis

ANOVA followed by the Tukey's multiple comparisons test was used for the analysis of data with more than two groups. Linear dependence of TGF-β1⁺ macrophages on Age at Onset (AO), Disease Burden (DB), Disability Scale (DS), Time from/to Onset (TO), UHDRS1, 2, 3, 4 scores and MMSE was determined by a simple regression model. Data were considered statistically significant at p < 0.05. Statistical analysis was performed with Biostat2009 software.

Additional files

Additional file 1: Total number of whole blood cells did not vary between HD individuals and healthy controls. A-C, Bar histograms showing total number of lymphocytic, granulocytic and monocyctic cells in both HD individuals (n = 81, gray bars) and healthy control subjects (n = 26, white bar). Whole blood cell populations were distinguished from each other on the basis of physical parameters by using forward (FSC-H, cell volume index) and side light-scatter patterns (SSC-H, cell density index). Cells number is expressed as n° cells × 10³/ml. Data are shown as mean ± s.d.

Additional file 2: Representative flow cytometric histograms showing TGF-β1⁺ monocytes in control subject (CTRL), pre-manifested subject (preHD) and stage HD patients (HD). TGF-β1⁺ cells were identified in FL-2⁺ fluorescence scatter (black histogram). Isotype control (gray histogram) was used to determine the 95% confidence interval of nonspecific fluorescence.

Additional file 3: Immunoblotting analysis showing changes of TGF-β1 expression at different disease stages. Representative immunoblot (top) and densitometric analysis (bottom) of TGF-β1 expression in healthy controls (CTRL, n = 4), pre-manifested subjects (pre-HD, n = 4) and severe HD patients (HD, n = 4). Bar graph represents the mean values ± s.d. * p < 0.05 (ANOVA followed by Tukey’s multiple comparisons test).

Additional file 4: Representative flow cytometric histograms showing TGF-β1⁺ macrophages in control subjects (CTRL), pre-manifested subjects (pre-HD) and stage HD patients (HD). TGF-β1⁺ cells were identified in FL-2⁺ fluorescence scatter (black histogram). Isotype control (gray histogram) was used to determine the 95% confidence interval of nonspecific fluorescence.

Additional file 5: Bar histograms showing no-age related changes in the percentage of TGF-β1⁺ macrophages in control subjects. A, Bar histograms showing percentage of TGF-β1⁺ macrophages in healthy controls divided into age groups (25–40, 41–55, 56–80). B, Bar histograms showing no changes of TGF-β1 content (MFU) in macrophages, from the same control individuals. Data are shown as mean ± s.d.
Additional file 6: Microglia appear not to be implicated in the synthesis of TGF-β1 in post-mortem brain tissues along HD course. Representative microphotographs of double fluorescent staining for TGF-β1 and Iba1 in post-mortem striatal tissues of control subjects (CTRL) and HD patients at different pathological grades (from I to IV). No colocalization between Iba1 immunoreactive cells and TGF-β1 immunopositive cells in none of the pathologically graded brains was observed.

Abbreviations
AO: Age at onset; BDNF: Brain derived neurotrophic factor; CAG: Cytosine adenosine guaninate; CCR2: C-C chemokine receptor type 2; CD14: Cluster differentiation 14; CD11b: Cluster differentiation 80; CNS: Central nervous system; CTRL: Healthy control; CypA: Cyclophilin A; CX3CR1: CX3 chemokine receptor 1; DAB: 3,3′-diaminobenzidine tetrachloride; DB: Disease burden; DS: Disability scale; FACS: Fluorescence activated cell sorting; FBS: Fetal bovine serum; FITC: Fluorescein isothiocyanate; GDNF: Glia derived neurotrophic factor; GPAP: Glial fibrillary acid protein; HD: Huntington disease; Htt: Huntingtin; Iba1: Ionized calcium-binding adaptor molecule 1; IL-10: Interleukine-10; IL-12: Interleukine-12; IL-6: Interleukine-6; M: Macrophages; MFU: Mean fluorescence unit; MMSE: Mini mental state examination; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; PBMC: Peripheral blood mononuclear cells; PBS: Phosphate-buffered saline; PMA: Phorbol 12-myristate 13-acetate; PPIA: Parvalbumin; PRF1: Proliferating cell nuclear antigen; PV: Primary visual cortex; RIA: Radioimmunoassay; RIPA: Radioimmunoassay; RPA: RNA polymerase; sGDNF: Soluble GDNF; TFC: Total functional score; TGF-β1: Transforming growth factor beta-1; UHDRS: Unified Huntington disease rating scale; yrs: years.

Competing interests
The authors declare no competing financial interests.

Authors' contributions
ADP, VM, GB, FN and FS contributed to project design, data analyses and paper writing. SA performed the majority of the experiments. EA, FE and CLB provided technical assistance. EC and JPV provided post-mortem brain samples and assistance with classification of neuropathological grade. All authors have read and approved the final manuscript.

Acknowledgement
We are grateful to all patients for contributing to our work. We thank Daniela Mazzullo, Serena Sciacca and Paola Paone for technical assistance. We are grateful to all patients for contributing to our work. We thank Vittorio Maglione is supported by a Marie Curie International Incoming Research Huntington e malattie correlate (www.lirh.it) onlus. Daniela Mazzullo, Serena Sciacca and Paola Paone for technical assistance. We are grateful to all patients for contributing to our work. We thank Acknowledgement
We are grateful to all patients for contributing to our work. We thank



References
1. van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol 2009, 8:765–774.
2. Björkqvist M, Wild EJ, Thieie J, Silvestoni A, Andre R, Lahiri H, Raboin E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Poulaud MA, Hayden MR, Khalili-Shariati A, Lowell MW, Brundin P, Bates GP, Leavitt BR, Møller T, Tabrizi SJ. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med 2008, 198:1869–1877.
3. Weiss A, Träger U, Wild EJ, Gueniger S, Farmer R, Landles C, Schalll RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ. Mutant huntingtin fragmentation in immune cells tracks Huntington disease’s progression. J Clin Invest 2012, 120:3731–3736.
4. Kwan W, Träger U, Davalos D, Chou A, Bouchard J, Andre R, Miller A, Weiss A, Gorgini F, Chieo C, Møller T, Stella N, Aksagotou K, Tabrizi SJ, Muchowski P. Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest 2012, 122:4737–4747.
5. Zuccato C, Ciarrapica A, Rigamonti D, Leavitt BR, Goffredo D, Zuccato C, Ciarrapica A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedländer RM, Slanić V, Hayden MR, Timms K, Tisonne IP, Cattaneo LE et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 2001, 252:493–498.
6. Marco S, Canudas AM, Canals JM, Gavaldà N, Pérez-Navarro E, Alberich J. Exocytic amino acids differentially regulate the expression of GDNF, neurotrophin, and their receptors in the adult rat striatum. Exp Neurol 2002, 2242–252.
7. Mattson NP. Glutamate and neurotoxic factors in neuronal plasticity and disease. Ann N Y Acad Sci 2008, 1144:97–112.
8. Gauthier LR, Charrin BC, Bornell-Pagès M, Dompierre JP, Rangone H, Cordelélias F, De Mey J, MacDonald ME, Lessmann V, Humbert H, Saadou F. Huntington controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127–138.
9. Boche D, Cunningham C, Docagne F, Scott H, Perry VH. TGFβ1 regulates the inflammatory response during chronic neurodegeneration. Neurobiol Dis 2006, 3:538–650.
10. Battaglia G, Carnella M, Rizzi B, Orboello M, Schiavon M, Aronica E, Busetti CL, Ciarmiello A, Alberti S, Amico E, Sassone J, Sipione S, Bruno V, Frati L, Nicotelli S, Squishei F. Early defect of transforming growth factor β1 formation in Huntington’s disease. J Cell Mol Med 2011, 15:555–571.
11. Denolle S, Goumans MJ, ten Oijike P. Transforming growth factor beta-1 signal transduction. J Leuk Biol 2002, 7:671–740.
12. Bironne TC, Tesser I, Masliah E, Wyss-Coray T. Loss of TGF-β1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 2003, 36:1133–1145.
13. Tesser I, Wyss-Coray T. A role for TGF-beta signaling in neurodegeneration: evidence from genetically engineered models. Curr Alzheimer Res 2006, 3:505–513.
14. Lee HG, Ueda M, Zhu X, Perry G, Smith MA. Ectopic expression of phospho-Smad2 in Alzheimer’s disease: uncoupling of the transforming growth factor-beta pathway? J Neuropathol Exp Neurol 2006, 65:1856–1861.
15. Tesser I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, Mucke L, Masliah E, Wyss-Coray T. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest 2006, 11:3060–3069.
16. Ueberham U, Ueberham E, Grußcha H, Arendt T. Altered subcellular location of phosphorylated Smads in Alzheimer’s disease. Eur J Neuropathol 2006, 2:2327–2334.
17. Chalmers KA, Love S. Neurofibillary tangles may interfere with Smad 2/3 signalling in neurons. J Neuropathol Exp Neurol 2007, 2:152–167.
18. Izavek J, Stelmiská Z, Dobroz B. Transforming growth factor-beta 1 (Tgf-Beta in patients with amyotrophic lateral sclerosis. Cytokine 2002, 2:229–234.
19. Lindholm D, Castren E, Kiefer R, Zafra F, Thoenen H. Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol 1992, 2:395–400.
20. Kupinski J, Kumar P, Kumar S, Kaluza A. Increased expression of TGF-beta 1 in brain tissue after ischemic stroke in humans. Stroke 1996, 2:852–857.
21. Boche D, Cunningham C, Gaudinle J, Perry VH. Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. J Cereb Blood Flow Metab 2003, 10:1174–1182.
22. Prud’homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007, 11:1207–1211.
23. Moiser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 12:958–969.
24. Stout RD, Jiang C, Matta B, Tietzel J, Watkins SK. Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005, 1862–349.
25. Friedson S. Alternative activation of macrophages. Nat Rev Immunol 2003, 12:3–35.
26. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009, 1:110–122.
27. Mantovani A, Sica A, Sozani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 12:671–680.
28. Connor B, Dragojlovic M: The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev 1998, 1:1–39.
29. Krutgen A, Saxena S, Evangelopoulos ME, Weis J: Neurotophins and neurodegenerative diseases: receptors stuck in traffic? J Neuropathol Exp Neurol 2003, 4:340–350.
30. Muger MG, Van O, Raisman-Vozari R: Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 2001, 7:1–72.
31. Zuccato C, Libor D, Ramos C, Tarditi A, Rigamonti D, Tartari M, Valenza M, Cattaneo E: Progressive loss of BDNF in a mouse model of Huntington’s disease and rescue by BDNF delivery. Pharmacol Res 2005, 2:133–139.
32. Cassette L, Cassel E, Poli G: Macrophage polarization in health and disease. ScientificWorldJournal 2011, 2:2391–2402.
33. Mantovani A, Sica A, Locati M: Macrophage polarization comes of age. Immunity 2005, 4:344–346.
34. Sica A, Mantovani A: Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012, 3:787–795.
35. Biswas SK, Mantovani A: Macrophage plasticity and polarization: in vivo expression of proinflammatory genes. Circulation 2008, 1337–1347.
36. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 2:953–964.
37. Mattson MP, Camandola S: NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001, 2:247–254.
38. Diessler F, Verstomk K, Sabat R, Aasalah K, Schottelius A: Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 2004, 1:64–73.
39. Hu J, Nakano H, Sakurai H, Colburn NH: Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and dysfunction in tumor development. Carcinogenesis 2004, 7:1991–2003.
40. Sica A, Broner V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 5:1155–1166.
41. Liu SF, Ye X, Malik AB: Inhibition of NF-kappaB activation by pyrroolidio dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 1999, 12:1330–1337.
42. Sica A, Saccani A, Bottazi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A: Autocrine production of IL-10 mediates defective IL-12 production and NF-kappaB activation in tumor-associated macrophages. J Immunol 2000, 2:762–767.
43. Porta C, Rimoldi M, Roa G, Blys G, Ghezzi P, Di Liberto D, Dieli F, Ghisletti S, Natoio G, De Baetselier P, Mantovani A, Sica A: Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A 2009, 3:14978–14983.
44. Liu SF, Malik AB: NF-kappaB activation as a pathological mechanism of septic shock and sepsis. Am J Physiol Lung Cell Mol Physiol 2006, 4:622–645.
45. Khoshnai A, Ko J, Watkin EE, Paige LA, Reinhardt PH, Patterson PH: Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 2004, 3:7999–8008.
46. Hsiao HY, Chen YC, Chen HM, Tu PH, Chen Y: A critical role of astrocyte-mediated nuclear factor-kB-dependent inflammation in Huntington’s disease. Hum Mol Genet 2013, 9:1826–1842.
47. Reijonen S, Kukkonen JP, Hyrskyluoto A, Kivinen J, Kaisalio M, Takei N, Lindholm D, Korhonen L: Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death. Cell Mol Life Sci 2010, 1:11929–1941.
48. Cao S, Zhang X, Edwards J, Mosser DM: NF-kappaB (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 2006, 3:26041–26050.
49. Grutz N: New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005, 3:13–15.
50. Bruno V, Battaglia G, Casabona G, Copani A, Cacciagli F, Nicolotti F: Neuroprotection by glial metabolotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 1998, 23:8994–9000.
51. Squiret F, Cannella M, Frati L: Molecular medicine: predicting and preventing Huntington’s disease. Neurol Sci 2008, 4:205–207.
52. Declaration of Helsinki: Law, medicine & health care: a publication of the American. Soc Law Med 1991, 3:4:264–265.
53. Huntington Study Group: The Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996, 1:136–142.
54. Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psych Res 1975, 2:189–198.
55. Squiret F, Geller C, Cannella M, Masiotti C, Ciladghi G, Rubinstein DC, Almqvist EW, Turner D, Bachoud-Levi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD: Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003, 4:946–955.
56. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttmann M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I: Huntington Study Group. Clinical markers of early disease in persons near onset of Huntington’s disease. Neurology 2001, 4:658–662.
57. Brinkman RR, Mezey MM, Thielmann J, Almqvist E, Hayden MR: The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997, 5:1202–1210.
58. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR: A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 2004, 3:267–277.
59. Di Paola M, Lenders E, Rubino IA, Siracusano A, Manfredi G, Girardi P, Martinotti G, Thompson PM, Chou YY, Togo AW, Martinotti G, Caltagirone C, Spalletta G: The structure of the corpus callosum in obsessive compulsive disorder. Eur Psychiatry 2012, 2:499–506.
60. Sánchez-Castañeda C, Cherubini A, Eliani F, Péran P, Orobello S, Capelli G, Sabatini U, Squarici F: Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp 2012, 2:1625–1635.
61. Penney JB, Voorsatell JP, MacDonald ME, Gusella JF, Myers RH: CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 1997, 2:689–692.
62. Myers RH, Voorsatell JP, Parkes PA, Kiely DK, Stevens TJ, Cupples LA, Richardson EP Jr, Bird ED: Decreased neurological and increased oligodendroglial densities in Huntington’s disease caudate nucleus. J Neuropathol Exp Neurol 1991, 6:729–742.
63. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB Jr, Siemers E, Shoulson I: Rate of functional decline in Huntington’s disease. Huntington Study Group 2000, 2:452–458.
64. Ganten F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmaher A: In vitro differentiation of human monocytes to macrophages: change of PDE4D expression in monocytes and macrophages. J Leukoc Biol 1999, 3:1338–1347.
65. Reynolds F, Reynolds R, Jr: Cerebellar granule cell transplantation: a new treatment for Huntington’s disease? Science 1998, 280:1669–1672.